Compare DexCom, Inc. (DXCM) vs MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs MicroSectors FANG and Innovation 3X Leveraged ETN — how do they compare? DexCom, Inc. trades at $90.79 (market cap $34.26B), while MicroSectors FANG and Innovation 3X Leveraged ETN trades at $32.43. The key difference: DexCom, Inc. is trading nearer its 52-week high, MicroSectors FANG and Innovation 3X Leveraged ETN nearer its low. Which is the better fit depends on your goals.
| DXCM | FNGU | |
|---|---|---|
Market Cap | $34.26B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $90.80 | $36.15 |
52-Week Low | $54.84 | $13.73 |
Enterprise Value | $33.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
FNGU, a 3X leveraged ETN tracking the FANG+ Index, trades at $32.19, down 4.48% on the day, with recent volatility highlighted by a 16% single-session drop on June 5, 2026. Technical indicators show a bullish moving average signal but overbought RSI levels, with key support at $32 and resistance at $34. The product's inherent leverage amplifies both gains and losses, as seen in recent performance gaps versus the underlying index.
The outlook for FNGU is highly speculative, driven by leveraged exposure to mega-cap tech stocks. Investment opportunity lies in magnified upside during strong bull markets, but risks are severe, including decay from daily rebalancing and extreme volatility. Investors face potential rapid capital erosion in downturns, as evidenced by recent sharp declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →
